ArticleAmerican journal of translational research2026
Imaging and clinicopathological features of a high-risk gastric stromal tumor: a case report.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo report upon the imaging and clinicopathological characteristics of a high-risk gastric stromal tumor (GST).
methodsA patient diagnosed with a GST at Shanghai Xuhui District Dahua Hospital and Shanghai Eighth People's Hospital in November 2021 was retrospectively analyzed. Clinical data, pathological features, immunohistochemical markers, c-kit/PDGFRA gene mutation status, and CT/MRI findings were collected.
resultsA 70-year-old male with a long history of smoking and alcohol use was diagnosed with a GST during a routine physical examination. The tumor exhibited high-risk features: a diameter of 7 cm, a mitotic count of 8/50 high-power fields, and location involving the submucosa and muscular layer. Immunohistochemistry revealed strong positivity for CD117 and CD34, positivity for DOG1, and a Ki-67 index <10%. Gene mutation analysis identified a heterozygous mutation in exon 11 of the c-kit gene (c.1676T>A p.Val559Asp), with no mutations detected in PDGFRA. Histologically, the tumor showed marked atypia with solid and cord-like growth patterns and conspicuous mitotic figures. Imaging demonstrated heterogeneous enhancement, ill-defined borders, irregular gastric wall thickening, calcification, and cystic/hemorrhagic changes. Notably, the patient remained recurrence- and metastasis-free for 4 years following surgical resection and adjuvant imatinib therapy.
conclusionThis case highlights the integration of pathological features, c-kit exon 11 mutation status, and imaging findings in the diagnosis and management of high-risk GSTs. The 4-year recurrence-free survival confirms the effectiveness of risk-stratified adjuvant therapy with imatinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.